Antiaging Quantum Living Inc (AAQL)

[DewDiligence]

JNJ licenses ACHN’s HCV pipeline—buys 18.4M shares @$12.25/sh (a 15% premium to today’s closing price):

http://finance.yahoo.com/news/janssen-enters-worldwide-collaboration-achillion-200500889.html

Achillion Pharmaceuticals, Inc. announced today that it has entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize one or more of Achillion's lead hepatitis C virus (HCV) assets which include ACH-3102, ACH-3422, and sovaprevir.

Under the terms of the agreement, Achillion will grant Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion's HCV assets. Achillion is eligible to receive a number of payments based upon achievement of specified development, regulatory and sales milestones. Achillion is also eligible to receive tiered royalty percentages between mid-teens and low-twenties based upon future worldwide sales. Janssen will be responsible for all of the development costs within the collaboration and all subsequent costs related to commercialization of the HCV assets.

…in an equity transaction separate to the exclusive license and collaboration arrangement, Johnson & Johnson Innovation…will invest $225 million in Achillion and, in return, receive approximately 18.4 million newly issued, unregistered shares of Achillion at a price of $12.25 per share.

Stock is currently halted.

CC at 5pm ET.